DWA
BCRX icon

Dorsey Wright & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dorsey Wright & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,086
Closed -$9K – 290
2019
Q1 		$9K Sell
1,086
-1,083
-50% -$9.27K ﹤0.01% 193
2018
Q4 		$18K Buy
+2,169
New +$16.9K 0.01% 146

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Dorsey Wright & Associates's BCRX Position: Q2 2019 in Review

Dorsey Wright & Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 1,086 shares — an estimated $9K sold.

Dorsey Wright & Associates first reported a position in BCRX in Q4 2018 and held it in 2 quarters. The position peaked at $18K in Q4 2018. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

  • Dorsey Wright & Associates reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,086 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $9K.
  • Dorsey Wright & Associates first reported a position in BioCryst Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Dorsey Wright & Associates's BioCryst Pharmaceuticals position peaked at $18K in Q4 2018.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Dorsey Wright & Associates's 13F filing for Q2 2019, filed 2 Jul 2019.